Rigel Reports Second Quarter 2025 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif., Aug. 5, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today reported financial results for the second quarter ended June 30, 2025, including sales of TAVALISSE^® (fostamatinib disodium hexahydrate), GAVRETO^® (pralsetinib) and REZLIDHIA^® (olutasidenib), and recent business progress.

Read more at prnewswire.com